If there was sufficient improvement in mortality that the trial might be unsuccessful yet still show a significant trend in favour of using Remestemcel-L, then why would the DSMB recommend terminating the trial with only 233 patients recruited? It must not have even been close, otherwise surely they would have let it continue.
The suspicion must be that if there was any improvement at all in mortality, it must have been so small that the DSMB wasn't prepared to continue with the trial. That doesn't suggest Novartis will be impressed. I guess we'll find out from their decision.
Novartis deal on the rocks, page-69
-
- There are more pages in this discussion • 179 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |